TABLE 3.
Crude mortality rate and hazard ratios by beta-blocker use.
| All beta-blockers users | Non-selective beta-blockers users | Selective beta-blocker users | Comparators | |
|---|---|---|---|---|
| Total, n | 604 | 89 | 515 | 1,387 |
| Follow-up time (years), median (IQR) | 2.72 (2.62) | 2.57 (2.92) | 2.77 (2.54) | 2.73 (2.90) |
| Breast cancer survival | ||||
| Breast cancer-related deaths, n (%) | 49 (8.1) | <6 (<6.7) a | <49 (<9.5) a | 105 (7.6) |
| Unadjusted sHR (95% CI) | 1.03 (0.74–1.45) | 0.60 (0.22–1.63) | 1.10 (0.78–1.56) | reference |
| Adjusted sHR b (95% CI) | 0.86 (0.58–1.28) | 0.42 (0.14–1.25) | 0.95 (0.63–1.43) | reference |
| All-cause survival | ||||
| All-cause deaths, n (%) | 98 (16.2) | 13 (14.6) | 85 (16.5) | 167 (12.0) |
| Unadjusted hazard ratios (95% CI) | 1.33 (1.03–1.70) | 1.28 (0.73–2.26) | 1.33 (1.03–1.73) | reference |
| Adjusted hazard ratios b (95% CI) | 1.02 (0.79–1.32) | 0.80 (0.45–1.42) | 1.07 (0.81–1.40) | reference |
CI, confidence interval; sHR, subdistribution hazard ratio; IQR, interquartile range.
a
Small cell suppression (<6) required by Australian Institute of Health and Welfare.
b
Adjusted for age group, weighted Charlson comorbidity index, congestive heart failure, myocardial infraction, metastasis at baseline (no metastasis vs. localized or distant metastasis), breast cancer molecular subtype and breast cancer surgery during the index hospitalization.